NURS 251 Pharmacology Complete Exam Bank Master
Bundle – Modules 1, 2, 3, 4, & 5 – 250 Questions with
Verified Answers and In-Depth Clinical Rationales – Portage
Learning / ABCnursing / Geneva College (Latest 2026/2027)
INSTANT PDF DOWNLOAD
Module 1: Foundational Principles of Pharmacokinetics & Pharmacodynamics
1. Which process describes the movement of a drug from its site of administration
into the systemic bloodstream?
A) Distribution
B) Metabolism
C) Absorption
D) Excretion
Rationale: Absorption is the specific pharmacokinetic phase that measures how a drug
travels from its point of entry (GI tract, muscle, skin) into the intravascular compartment.
2. When an oral medication undergoes extensive inactivation within the portal
venous system prior to systemic distribution, this represents:
A) Glomerular filtration clearance
B) The first-pass effect
C) Post-receptor down-regulation
D) Subcutaneous tissue depot trapping
Rationale: The first-pass effect occurs when drugs absorbed from the gastrointestinal
tract pass directly into the liver via the portal vein, where hepatic enzymes metabolize a
significant fraction of the drug before it reaches the rest of the body.
3. A nurse administers a drug with a high affinity for plasma albumin. If the patient
has severe hypoalbuminemia, what pharmacokinetic consequence should the nurse
expect?
A) The drug will be completely inactivated.
B) There will be an increase in the fraction of free, active drug, raising the risk of
toxicity.
C) Intestinal absorption of the drug will fall to zero.
D) Renal clearance of the drug will slow down completely.
Rationale: Only unbound ("free") drug molecules can cross capillary membranes to
,exert pharmacological actions or be cleared. Low serum albumin levels mean fewer binding
sites, leaving more free, active drug in circulation.
4. Which parameter defines the percentage of an administered drug dose that
reaches the systemic circulation in an unchanged, active form?
A) Half-life
B) Bioavailability
C) Therapeutic index
D) Volume of distribution
Rationale: Bioavailability measures the fraction of an un-metabolized drug dose that
reaches the systemic bloodstream. Intravenous administration offers 100% bioavailability by
definition.
5. The primary organ system responsible for the metabolic biotransformation of lipid-
soluble drugs into water-soluble metabolites is the:
A) Kidneys
B) Lungs
C) Liver
D) Exocrine sweat glands
Rationale: The liver uses the cytochrome P450 enzyme system to convert lipid-soluble
compounds into water-soluble metabolites that the kidneys can easily excrete.
6. A drug has a biological half-life (\(t_{1/2}\)) of 4 hours. If a single dose is given,
approximately how many hours will it take for the drug to be considered cleared
(>94% eliminated) from the body?
A) 4 hours
B) 8 hours
C) 12 hours
D) 16 to 20 hours
Rationale: It takes roughly 4 to 5 half-lives for a drug to be eliminated from the body. At
4 hours per half-life, 4 to 5 cycles equals 16 to 20 hours.
7. What is the definition of a drug's "Therapeutic Index" (TI)?
A) The total time required for a drug to reach its maximum peak serum level
B) The ratio between a drug's toxic dose and its minimum effective therapeutic dose
C) The total number of receptor subtypes a single drug molecule can bind to
D) The percentage of drug bound to red blood cell membranes
Rationale: The therapeutic index measures a drug's safety margin. A narrow therapeutic
,index means the effective dose is very close to the toxic dose, requiring regular plasma
level monitoring.
8. An antagonist medication is best characterized by which properties?
A) High affinity and high intrinsic activity
B) High affinity but zero intrinsic activity
C) Low affinity and high intrinsic activity
D) Zero affinity and zero intrinsic activity
Rationale: Antagonists possess the affinity needed to bind to a receptor site, but they
lack intrinsic activity. This means they do not activate the receptor; instead, they block
endogenous ligands from binding.
9. Which transport mechanism requires cellular energy (ATP) to move a drug
molecule against its concentration gradient across a membrane?
A) Passive diffusion
B) Facilitated diffusion
C) Active transport
D) Osmotic filtration
Rationale: Active transport relies on carrier proteins and ATP energy to pump drug
molecules across cell membranes against a concentration gradient.
10. When a patient takes a known Cytochrome P450 enzyme inducer alongside
another medication, what effect will this have on the second medication?
A) It will accelerate the metabolism of the second medication, potentially decreasing
its therapeutic effect.
B) It will inhibit the breakdown of the second drug, causing severe toxicity.
C) It will increase the absorption rate of the second drug through the stomach lining.
D) It will permanently neutralize the second drug's ability to bind to target tissues.
Rationale: Enzyme inducers stimulate the synthesis of hepatic metabolic enzymes. This
accelerates the breakdown of concurrent medications, lowering their plasma concentrations
and therapeutic effectiveness.
🫁 Module 2: Autonomic Nervous System & Respiratory Pharmacology
11. Stimulating Parasympathetic Muscarinic receptors leads to which physiological
response?
, A) Bronchodilation and tachycardia
B) Mydriasis and urinary retention
C) Bronchoconstriction, bradycardia, and increased gastrointestinal motility
D) Vasoconstriction and inhibition of salivation
Rationale: The parasympathetic nervous system governs "rest and digest" functions.
Activating muscarinic receptors slows the heart rate (bradycardia), constricts the airways
(bronchoconstriction), and stimulates secretions and digestion.
12. Which drug serves as the first-line choice for reversing a severe, life-threatening
anaphylactic reaction?
A) Albuterol
B) Atropine
C) Epinephrine
D) Metoprolol
Rationale: Epinephrine is a non-selective adrenergic agonist. Its alpha-1 activity treats
hypotension through vasoconstriction, its beta-1 activity supports cardiac output, and its
beta-2 activity reverses bronchospasm.
13. What is the primary mechanism of action of Albuterol?
A) It blocks muscarinic cholinergic receptors in airway smooth muscle.
B) It selectively stimulates Beta-2 adrenergic receptors, causing bronchodilation.
C) It stabilizes mast cell membranes to prevent histamine release.
D) It inhibits phosphodiesterase enzymes to reduce inflammation.
Rationale: Albuterol is a short-acting beta-2 agonist (SABA) that relaxes bronchial
smooth muscle to provide rapid relief during acute bronchospasms.
14. A patient is prescribed lpratropium bromide for chronic obstructive pulmonary
disease (COPD). This medication belongs to which drug class?
A) Beta-2 adrenergic agonist
B) Anticholinergic / Muscarinic antagonist
C) Leukotriene receptor modifier
D) Methylxanthine derivative
Rationale: Ipratropium is an anticholinergic drug that blocks muscarinic receptors in the
lungs, inhibiting parasympathetic bronchoconstriction to help keep airways open.
15. What is an expected systemic side effect of an oral Corticosteroid like
Prednisone?
A) Severe hypoglycemia
B) Hyperglycemia, fluid retention, and delayed wound healing
Bundle – Modules 1, 2, 3, 4, & 5 – 250 Questions with
Verified Answers and In-Depth Clinical Rationales – Portage
Learning / ABCnursing / Geneva College (Latest 2026/2027)
INSTANT PDF DOWNLOAD
Module 1: Foundational Principles of Pharmacokinetics & Pharmacodynamics
1. Which process describes the movement of a drug from its site of administration
into the systemic bloodstream?
A) Distribution
B) Metabolism
C) Absorption
D) Excretion
Rationale: Absorption is the specific pharmacokinetic phase that measures how a drug
travels from its point of entry (GI tract, muscle, skin) into the intravascular compartment.
2. When an oral medication undergoes extensive inactivation within the portal
venous system prior to systemic distribution, this represents:
A) Glomerular filtration clearance
B) The first-pass effect
C) Post-receptor down-regulation
D) Subcutaneous tissue depot trapping
Rationale: The first-pass effect occurs when drugs absorbed from the gastrointestinal
tract pass directly into the liver via the portal vein, where hepatic enzymes metabolize a
significant fraction of the drug before it reaches the rest of the body.
3. A nurse administers a drug with a high affinity for plasma albumin. If the patient
has severe hypoalbuminemia, what pharmacokinetic consequence should the nurse
expect?
A) The drug will be completely inactivated.
B) There will be an increase in the fraction of free, active drug, raising the risk of
toxicity.
C) Intestinal absorption of the drug will fall to zero.
D) Renal clearance of the drug will slow down completely.
Rationale: Only unbound ("free") drug molecules can cross capillary membranes to
,exert pharmacological actions or be cleared. Low serum albumin levels mean fewer binding
sites, leaving more free, active drug in circulation.
4. Which parameter defines the percentage of an administered drug dose that
reaches the systemic circulation in an unchanged, active form?
A) Half-life
B) Bioavailability
C) Therapeutic index
D) Volume of distribution
Rationale: Bioavailability measures the fraction of an un-metabolized drug dose that
reaches the systemic bloodstream. Intravenous administration offers 100% bioavailability by
definition.
5. The primary organ system responsible for the metabolic biotransformation of lipid-
soluble drugs into water-soluble metabolites is the:
A) Kidneys
B) Lungs
C) Liver
D) Exocrine sweat glands
Rationale: The liver uses the cytochrome P450 enzyme system to convert lipid-soluble
compounds into water-soluble metabolites that the kidneys can easily excrete.
6. A drug has a biological half-life (\(t_{1/2}\)) of 4 hours. If a single dose is given,
approximately how many hours will it take for the drug to be considered cleared
(>94% eliminated) from the body?
A) 4 hours
B) 8 hours
C) 12 hours
D) 16 to 20 hours
Rationale: It takes roughly 4 to 5 half-lives for a drug to be eliminated from the body. At
4 hours per half-life, 4 to 5 cycles equals 16 to 20 hours.
7. What is the definition of a drug's "Therapeutic Index" (TI)?
A) The total time required for a drug to reach its maximum peak serum level
B) The ratio between a drug's toxic dose and its minimum effective therapeutic dose
C) The total number of receptor subtypes a single drug molecule can bind to
D) The percentage of drug bound to red blood cell membranes
Rationale: The therapeutic index measures a drug's safety margin. A narrow therapeutic
,index means the effective dose is very close to the toxic dose, requiring regular plasma
level monitoring.
8. An antagonist medication is best characterized by which properties?
A) High affinity and high intrinsic activity
B) High affinity but zero intrinsic activity
C) Low affinity and high intrinsic activity
D) Zero affinity and zero intrinsic activity
Rationale: Antagonists possess the affinity needed to bind to a receptor site, but they
lack intrinsic activity. This means they do not activate the receptor; instead, they block
endogenous ligands from binding.
9. Which transport mechanism requires cellular energy (ATP) to move a drug
molecule against its concentration gradient across a membrane?
A) Passive diffusion
B) Facilitated diffusion
C) Active transport
D) Osmotic filtration
Rationale: Active transport relies on carrier proteins and ATP energy to pump drug
molecules across cell membranes against a concentration gradient.
10. When a patient takes a known Cytochrome P450 enzyme inducer alongside
another medication, what effect will this have on the second medication?
A) It will accelerate the metabolism of the second medication, potentially decreasing
its therapeutic effect.
B) It will inhibit the breakdown of the second drug, causing severe toxicity.
C) It will increase the absorption rate of the second drug through the stomach lining.
D) It will permanently neutralize the second drug's ability to bind to target tissues.
Rationale: Enzyme inducers stimulate the synthesis of hepatic metabolic enzymes. This
accelerates the breakdown of concurrent medications, lowering their plasma concentrations
and therapeutic effectiveness.
🫁 Module 2: Autonomic Nervous System & Respiratory Pharmacology
11. Stimulating Parasympathetic Muscarinic receptors leads to which physiological
response?
, A) Bronchodilation and tachycardia
B) Mydriasis and urinary retention
C) Bronchoconstriction, bradycardia, and increased gastrointestinal motility
D) Vasoconstriction and inhibition of salivation
Rationale: The parasympathetic nervous system governs "rest and digest" functions.
Activating muscarinic receptors slows the heart rate (bradycardia), constricts the airways
(bronchoconstriction), and stimulates secretions and digestion.
12. Which drug serves as the first-line choice for reversing a severe, life-threatening
anaphylactic reaction?
A) Albuterol
B) Atropine
C) Epinephrine
D) Metoprolol
Rationale: Epinephrine is a non-selective adrenergic agonist. Its alpha-1 activity treats
hypotension through vasoconstriction, its beta-1 activity supports cardiac output, and its
beta-2 activity reverses bronchospasm.
13. What is the primary mechanism of action of Albuterol?
A) It blocks muscarinic cholinergic receptors in airway smooth muscle.
B) It selectively stimulates Beta-2 adrenergic receptors, causing bronchodilation.
C) It stabilizes mast cell membranes to prevent histamine release.
D) It inhibits phosphodiesterase enzymes to reduce inflammation.
Rationale: Albuterol is a short-acting beta-2 agonist (SABA) that relaxes bronchial
smooth muscle to provide rapid relief during acute bronchospasms.
14. A patient is prescribed lpratropium bromide for chronic obstructive pulmonary
disease (COPD). This medication belongs to which drug class?
A) Beta-2 adrenergic agonist
B) Anticholinergic / Muscarinic antagonist
C) Leukotriene receptor modifier
D) Methylxanthine derivative
Rationale: Ipratropium is an anticholinergic drug that blocks muscarinic receptors in the
lungs, inhibiting parasympathetic bronchoconstriction to help keep airways open.
15. What is an expected systemic side effect of an oral Corticosteroid like
Prednisone?
A) Severe hypoglycemia
B) Hyperglycemia, fluid retention, and delayed wound healing
